IRIS
FERONE, DIEGO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 35.778
NA - Nord America 4.329
AS - Asia 3.967
Continente sconosciuto - Info sul continente non disponibili 631
SA - Sud America 373
AF - Africa 82
OC - Oceania 4
Totale 45.164
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 35.085
US - Stati Uniti d'America 4.043
SG - Singapore 1.536
CN - Cina 965
VN - Vietnam 619
BD - Bangladesh 449
FR - Francia 297
BR - Brasile 223
HK - Hong Kong 118
FI - Finlandia 109
CA - Canada 100
GB - Regno Unito 75
DE - Germania 65
AR - Argentina 57
MX - Messico 50
JP - Giappone 41
IN - India 33
JM - Giamaica 33
IQ - Iraq 32
CO - Colombia 27
ID - Indonesia 27
EC - Ecuador 26
PH - Filippine 21
VE - Venezuela 20
NL - Olanda 19
ZA - Sudafrica 19
CH - Svizzera 18
CR - Costa Rica 18
TR - Turchia 18
ES - Italia 17
GT - Guatemala 16
TH - Thailandia 15
IE - Irlanda 14
SA - Arabia Saudita 14
HN - Honduras 13
CL - Cile 11
RU - Federazione Russa 11
DZ - Algeria 10
SV - El Salvador 10
MY - Malesia 9
NI - Nicaragua 9
PK - Pakistan 9
TT - Trinidad e Tobago 9
NP - Nepal 8
TW - Taiwan 8
AE - Emirati Arabi Uniti 7
JO - Giordania 7
KE - Kenya 7
MA - Marocco 7
PL - Polonia 7
UA - Ucraina 7
SC - Seychelles 6
TN - Tunisia 6
BB - Barbados 5
DO - Repubblica Dominicana 5
KZ - Kazakistan 5
LB - Libano 5
SE - Svezia 5
AT - Austria 4
BY - Bielorussia 4
EE - Estonia 4
HR - Croazia 4
PR - Porto Rico 4
RO - Romania 4
UZ - Uzbekistan 4
AG - Antigua e Barbuda 3
AL - Albania 3
AU - Australia 3
BG - Bulgaria 3
BO - Bolivia 3
CI - Costa d'Avorio 3
CZ - Repubblica Ceca 3
EG - Egitto 3
ET - Etiopia 3
LC - Santa Lucia 3
LT - Lituania 3
MU - Mauritius 3
NG - Nigeria 3
NO - Norvegia 3
PE - Perù 3
RS - Serbia 3
AZ - Azerbaigian 2
BE - Belgio 2
CW - ???statistics.table.value.countryCode.CW??? 2
GR - Grecia 2
IL - Israele 2
KR - Corea 2
KW - Kuwait 2
MM - Myanmar 2
OM - Oman 2
PY - Paraguay 2
VI - Stati Uniti Isole Vergini 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BN - Brunei Darussalam 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BS - Bahamas 1
BZ - Belize 1
CD - Congo 1
Totale 44.511
Salva come PNG Salva come JPEG
Città #
Genova 21.519
Genoa 8.355
Rapallo 2.417
Vado Ligure 2.268
San Jose 968
Singapore 715
Ashburn 400
Lauterbourg 272
Ho Chi Minh City 176
New York 157
Beijing 149
Hanoi 149
Hong Kong 115
Santa Clara 115
Council Bluffs 112
Helsinki 95
Milan 79
Los Angeles 76
Phoenix 64
Chicago 50
Dallas 50
Frankfurt am Main 48
Rome 46
Bordighera 39
Tokyo 39
Buffalo 32
Haiphong 32
Boardman 29
Atlanta 27
Mexico City 27
Da Nang 25
Orem 24
São Paulo 24
San Francisco 22
Newark 21
Philadelphia 21
Bologna 18
Houston 18
Kingston 18
Naples 18
Tianjin 18
Turin 18
Brooklyn 17
Charlotte 17
Zurich 16
London 15
Toronto 15
Miami 14
Montreal 14
Dublin 13
Lappeenranta 13
San José 13
The Bronx 13
Cardiff 12
Hamilton 12
City of London 11
Guangzhou 11
Guatemala City 11
Palermo 11
Can Tho 10
Denver 10
Ilion 10
Memphis 10
Quito 10
San Antonio 10
San Salvador 10
Baghdad 9
Biên Hòa 9
Bogotá 9
Brasília 9
Hải Dương 9
Las Vegas 9
Managua 9
Modena 9
Queens 9
Birmingham 8
Brescia 8
Buenos Aires 8
Cleveland 8
Florence 8
Jacksonville 8
Nuremberg 8
Seattle 8
Shanghai 8
Agawam 7
Amman 7
Amsterdam 7
Bari 7
Columbus 7
Des Moines 7
Garland 7
Guayaquil 7
Johannesburg 7
Louisville 7
Nairobi 7
Pittsburgh 7
Quận Ba 7
San Diego 7
Thái Bình 7
Warsaw 7
Totale 39.428
Salva come PNG Salva come JPEG
Nome #
Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins 328
Acute and chronic effects of octreotide on thyroid axis in GH-secreting and clinically nonfuctioning pituitary adenomas. 265
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients 250
Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs? 244
Autonomic nervous system and cardiovascular risk assessment during one year of growth hormone (GH) replacement therapy in adults with GH deficiency. 242
Neuroendocrine-immune interactions: the role of cortistatin/somatostatin system 241
Current perspectives in obesity management: unraveling the impact of different therapy approach in real life obesity care 237
Clinical outcome and evidence of high rate post-surgical anterior hypopituitarism in a cohort of TSH-secreting adenoma patients: Might somatostatin analogs have a role as first-line therapy? 230
Diffuse Endocrine System, Neuroendocrine Tumors and Immunity: What's New? 228
Conventional and nuclear medicine imaging in Ectopic Cushing's syndrome: A systematic review 227
Acromegaly is associated with increased cancer risk: A survey in Italy 227
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study 226
Autoimmune central diabetes insipidus in a patient with ureaplasma urealyticum infection and review on new triggers of immune response. 217
SOMATOSTATIN AND DOPAMINE RECEPTOR INTERACTION IN PROSTATE AND LUNG CANCER CELL LINES 216
Effect of environment on growth: auxological and hormonal parameters in African and Italian children 216
Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells 216
Diabetes secondary to neuroendocrine gastroenteropancreatic tumors 215
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management 213
Increased mammographic breast density in acromegaly: quantitative and qualitative assessment. 211
Computed tomography colonography in acromegaly 209
Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS) 209
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids 208
Pituitary image: pituicytoma. 207
Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases 199
Calcitonin assay in wash-out fluid after fine-needle aspiration biopsy in patients with a thyroid nodule and border-line value of the hormone 198
The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology 197
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient 194
Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas 194
Adult iatrogenic Cushing's syndrome induced by topical skin corticosteroid misuse 194
Partial visual recovery from radiation-induced optic neuropathy after hyperbaric oxygen therapy in a patient with Cushing disease 193
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogs and dopastatins 193
Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms 193
Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study 191
(99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy. 191
Emerging targets in pituitary adenomas: role of the CXCL12/CXCR4-R7 system 190
Biochemical diagnosis and assessment of disease activity in acromegaly: a two-decade experience. 189
Hormone receptors analysis in idiopathic progressive subglottic stenosis 188
"Present and future of immunotherapy in Neuroendocrine Tumors" 188
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD 186
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas 186
Characterization and sub-cellular localization of SS1R, SS2R, and SS5R in human late-stage prostate cancer cells: effect of mono- and bi-specific somatostatin analogs on cell growth. 186
A unique association of clinical "persistent müllerian duct syndrome" and syringoid carcinoma of the perineal-scrotal skin: a consequence of urologic surgery? 186
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system 185
Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors 184
Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study. 183
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 182
KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment ? 181
The pathology of the ulnar nerve in acromegaly. 180
Effect of corticotrophin-releasing hormone administration on growth hormone levels in acromegaly: in vivo and in vitro studies. 179
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database 179
One-year GH replacement therapy reduces early cardiac target organ damage (TOD) in adult GHD patients 176
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell? 176
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas 175
A pilot study on nerve ultrasound in acromegaly 174
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation 172
On-field evaluation of a ultra-rapid fluorescence immunoassay as a frontline test for SARS-CoV-2 diagnostic 171
Role of pituitary dysfunction on cardiovascular risk in primary empty sella patients. 170
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities 169
Systemic complications of acromegaly: epidemiology, pathogenesis, and management 168
Grade increases in gastroenteropancreatic neuroendocrine tumor metastases compared to the primary tumor 168
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. 167
CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab 166
Vasopressin levels in Cushing’s disease: inferior petrosal sinus assay, response to corticotrophin-releasing hormone and comparison with patients without Cushing’s disease. 165
Managing Cushing's disease: The state of the art 165
High prevalence of vitamin D deficiency and its association with left ventricular dilation: an echocardiography study in elderly patients with chronic heart failure 164
Doe4s biopsy reliably identify grade in gastro-entero-pancreatic neuroendocrine tumors? 164
Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures 164
Somatostatin receptor scintigraphy in thoracic diseases 163
Normal age-dependent values of serum insulin growth factor-I: results from a healthy Italian population 163
Initial staging of lymphoma with octreotide and other receptor imaging agents. 163
Endoscopic endonasal transsphenoidal approach: An additional reason in support of surgery in the management of pituitary lesions. 163
Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly 163
Somatostatin receptor ligands in the treatment of acromegaly 163
Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study 163
Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? 163
Polycythemia as rare secondary direct manifestation of acromegaly: management and single-centre epidemiological data. 163
Octreotide and pasireotide combination treatment in somatotroph tumor cells: Predominant role of sst2 in mediating ligand effects 163
A phase 2 trial of long-acting TransCon growth hormone in adult GH deficiency 162
Leptin, ghrelin, and adiponectin evaluation in transsexual subjects during hormonal treatments 161
Rare diseases in clinical endocrinology: A taxonomic classification system 161
Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly 161
Clinical and radiological presentation of parasellar ectopic pituitary adenomas: case series and systematic review of the literature 160
Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies 160
Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients 160
Significant tumour shrinkage after 12 months of Lanreotide Autogel-120 mg treatment given first-line in acromegaly 159
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center 159
A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update 159
Dopamine receptor expression and function in corticotroph ectopic tumors. 158
Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. 158
Plasma atrial natriuretic factor levels in the inferior petrosal sinus blood of patients with Cushing’s disease before and after corticotropin-releasing hormone administration. 158
Pituitary tumor disappearance in a patient with newly diagnosed acromegaly primarily treated with octreotide LAR 157
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. 157
Trigger Finger, an Early Musculoskeletal Manifestation of Acromegaly 157
Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly 157
Emerging drugs for the treatment of acromegaly 157
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. 156
Sympathovagal imbalance in acromegalic patients 156
Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database 156
T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly 155
Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency 154
Totale 18.513
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.005
article - articoli 148.655
book - libri 0
conference - conferenze 737
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 613
Totale 300.010
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.107 0 0 283 437 90 251 257 736 174 317 163 399
2022/20232.958 329 208 39 270 442 524 23 219 531 26 302 45
2023/20241.652 90 221 39 186 131 283 108 69 100 66 100 259
2024/20255.496 153 423 155 368 781 573 564 784 247 267 502 679
2025/202610.587 1.078 332 1.010 921 1.120 1.032 1.611 419 774 889 650 751
2026/20272.523 1.192 522 809 0 0 0 0 0 0 0 0 0
Totale 45.164